In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Avanos Medical’s current price exceeds its high-confidence fair value estimate by 47%, indicating overvaluation risk. The DCF model shows significant negative valuation, contrasting with higher price/sales and analyst targets, revealing model divergence and valuation uncertainty. Strong liquidity contrasts with weak profitability and growth, suggesting financial stability amid operational challenges.